Trial Profile
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs MB-103 (Primary) ; MB-103 (Primary)
- Indications Glioma
- Focus Adverse reactions
- 02 Jan 2024 Planned End Date changed from 14 Dec 2023 to 14 Jun 2024.
- 02 Jan 2024 Planned primary completion date changed from 14 Dec 2023 to 14 Jun 2024.
- 19 Jun 2023 Planned End Date changed from 15 Dec 2023 to 14 Dec 2023.